FibroGen (NASDAQ:FGEN) Now Covered by StockNews.com

StockNews.com began coverage on shares of FibroGen (NASDAQ:FGEN) in a report released on Wednesday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

FibroGen Price Performance

NASDAQ FGEN opened at $0.31 on Wednesday. The company has a 50 day simple moving average of $0.37 and a 200-day simple moving average of $0.74. FibroGen has a 52-week low of $0.29 and a 52-week high of $2.93.

FibroGen (NASDAQ:FGEN) last released its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.09. The company had revenue of $50.64 million during the quarter, compared to analysts’ expectations of $33.00 million. During the same quarter in the previous year, the company earned ($0.65) EPS. Research analysts predict that FibroGen will post -0.91 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of FGEN. Alpine Global Management LLC acquired a new stake in shares of FibroGen during the 1st quarter valued at about $25,000. Delap Wealth Advisory LLC bought a new stake in FibroGen in the first quarter worth approximately $27,000. Acadian Asset Management LLC grew its position in FibroGen by 1.4% in the first quarter. Acadian Asset Management LLC now owns 2,503,865 shares of the biopharmaceutical company’s stock worth $5,883,000 after acquiring an additional 34,937 shares in the last quarter. Sei Investments Co. increased its stake in shares of FibroGen by 38.4% during the 2nd quarter. Sei Investments Co. now owns 149,342 shares of the biopharmaceutical company’s stock worth $133,000 after purchasing an additional 41,442 shares during the last quarter. Finally, Point72 DIFC Ltd raised its holdings in shares of FibroGen by 734.2% during the 2nd quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 45,990 shares in the last quarter. 72.71% of the stock is owned by institutional investors and hedge funds.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.